Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy

CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors

(2021) Huanpeng Chen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase 1 Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2021) Stephen M Ansell et al.   CLINICAL CANCER RESEARCH

CAR T cells in solid tumors: challenges and opportunities

(2021) Faroogh Marofi et al.   Stem Cell Research & Therapy

Brexucabtagene Autoleucel Therapy Induces Complete Remission in a Primary Refractory Blastoid Mantle Cell Lymphoma with Neurolymphomatosis

(2021) Arushi Khurana et al.   AMERICAN JOURNAL OF HEMATOLOGY

Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential

(2020) Linlin Ma et al.   JOURNAL OF NANOBIOTECHNOLOGY

The CD47-SIRPα Immune Checkpoint

(2020) Meike E.W. Logtenberg et al.   IMMUNITY

Memory T cells: strategies for optimizing tumor immunotherapy

(2020) Qingjun Liu et al.   Protein & Cell

Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance

(2020) Vanessa Gauttier et al.   JOURNAL OF CLINICAL INVESTIGATION

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

(2020) Gils Roex et al.   Journal of Hematology & Oncology

An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer

(2019) Steven Feins et al.   AMERICAN JOURNAL OF HEMATOLOGY

Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma

(2019) Ying Liu et al.   JOURNAL OF IMMUNOLOGY

Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice

(2019) Yushu Joy Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SIRP α/ CD 47 axis controls the maintenance of transplant tolerance sustained by myeloid‐derived suppressor cells

(2019) Sabrina Pengam et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Thrombospondin-1/CD47 Interaction Regulates Th17 and Treg Differentiation in Psoriasis

(2019) Pedro Rodríguez-Jiménez et al.   Frontiers in Immunology

T cell senescence and CAR-T cell exhaustion in hematological malignancies

(2018) Dimitri Kasakovski et al.   Journal of Hematology & Oncology

IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor

(2018) Keishi Adachi et al.   NATURE BIOTECHNOLOGY

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System

(2018) Mauro P. Avanzi et al.   Cell Reports

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

(2018) Sarwish Rafiq et al.   NATURE BIOTECHNOLOGY

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anticancer effects of anti-CD47 immunotherapy in vivo

(2018) Kristina Iribarren et al.   OncoImmunology

Cancer immunotherapy targeting the CD47/SIRPα axis

(2017) Kipp Weiskopf   EUROPEAN JOURNAL OF CANCER

The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer

(2017) Hanke L. Matlung et al.   IMMUNOLOGICAL REVIEWS

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Microenvironment and Differential Responses to Therapy

(2017) Eishu Hirata et al.   Cold Spring Harbor Perspectives in Medicine

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

(2016) Penka S. Petrova et al.   CLINICAL CANCER RESEARCH

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

(2016) Vinit Kumar et al.   TRENDS IN IMMUNOLOGY

Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas

(2016) A. H. Long et al.   Cancer Immunology Research

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

(2015) Soranobu Ninomiya et al.   BLOOD

Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T

(2015) Rachel A. Burga et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Overcoming T cell exhaustion in infection and cancer

(2015) Kristen E. Pauken et al.   TRENDS IN IMMUNOLOGY

The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target

(2013) A. Neil Barclay et al.   Annual Review of Immunology

CD47high Expression on CD4 Effectors Identifies Functional Long-Lived Memory T Cell Progenitors

(2012) V. Q. Van et al.   JOURNAL OF IMMUNOLOGY

CD47Low Status on CD4 Effectors Is Necessary for the Contraction/Resolution of the Immune Response in Humans and Mice

(2012) Vu Quang Van et al.   PLoS One

A human memory T cell subset with stem cell–like properties

(2011) Luca Gattinoni et al.   NATURE MEDICINE

CD47 in the Immune Response: Role of Thrombospondin and SIRP-α Reverse Signaling

(2008) Marika Sarfati et al.   CURRENT DRUG TARGETS